<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087888</url>
  </required_header>
  <id_info>
    <org_study_id>PA18-0719</org_study_id>
    <secondary_id>NCI-2021-09725</secondary_id>
    <secondary_id>PA18-0719</secondary_id>
    <nct_id>NCT05087888</nct_id>
  </id_info>
  <brief_title>MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation</brief_title>
  <official_title>Investigation of Serial Advanced Magnetic Resonance Imaging (MRI) and Biofluid Biomarkers Predictive of Neurocognitive Decline Following Brain Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This study determines whether non-invasive evaluation using repeated magnetic resonance&#xD;
      imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes&#xD;
      in a person's mental functions that result from radiation exposure to the brain. This study&#xD;
      may let researchers monitor patient responses to treatment and the disease better and&#xD;
      possibly make changes to patient treatment, if needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To describe changes of image features on conventional T1- and T2- weighted imaging, and&#xD;
      quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC),&#xD;
      fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the&#xD;
      extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the&#xD;
      diffusive transport of low-molecular weight gadolinium across the capillary endothelium)&#xD;
      associated with neurocognitive changes following radiation.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To identify biofluid biomarkers at baseline and dynamics of biomarkers after radiation&#xD;
      exposure that are associated with neurocognitive changes.&#xD;
&#xD;
      II. To model a composite early biomarker (baseline or within 3 weeks of the start of&#xD;
      radiotherapy) that incorporates the most promising imaging and biofluid biomarkers to predict&#xD;
      for later neurocognitive decline.&#xD;
&#xD;
      III. To evaluate the relationship between the delivered radiation dosimetry to brain&#xD;
      subregions and patterns of neurocognitive decline in order to inform potential subregions of&#xD;
      focus for future pre-clinical and clinical investigation.&#xD;
&#xD;
      IV. To evaluate the relationship between quantitative changes on multiparametric MRI&#xD;
      including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral&#xD;
      blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and&#xD;
      Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight&#xD;
      gadolinium across the capillary endothelium) with radiation dosimetry.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To explore changes on advanced MR measurements of structural connectomics, functional&#xD;
      connectomics, working memory network, cerebrovascular reactivity (CVR), cerebral blood flow&#xD;
      (CBF) and brain metabolism associated with neurocognitive changes following radiation.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy,&#xD;
      and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI&#xD;
      without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo&#xD;
      functional MRI at baseline and 6 months post-radiotherapy. Patients also complete&#xD;
      questionnaires and undergo collection of blood samples at baseline, weekly through week 6&#xD;
      during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe changes of image features on conventional T1- and T2- weighted imaging, and quantitative changes on the multipara metric MRI.</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (MRI, questionnaire, blood collection)</arm_group_label>
    <description>Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (MRI, questionnaire, blood collection)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo functional MRI</description>
    <arm_group_label>Observational (MRI, questionnaire, blood collection)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multiparametric Magnetic Resonance Imaging</intervention_name>
    <description>Undergo multiparametric MRI</description>
    <arm_group_label>Observational (MRI, questionnaire, blood collection)</arm_group_label>
    <other_name>MP-MRI</other_name>
    <other_name>mpMRI</other_name>
    <other_name>Multi-parametric MRI</other_name>
    <other_name>Multiparametric MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (MRI, questionnaire, blood collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing central nervous system (CNS) or head and neck (H&amp;N) radiotherapy with&#xD;
        radiation exposure to the brain to investigate the pattern of neurocognitive changes in&#xD;
        relation to brain dosimetry and associated imaging and biofluid biomarkers predictive of&#xD;
        neurocognitive outcomes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be age &gt;= 18 years&#xD;
&#xD;
          -  Patients must be planned for fractionated radiotherapy that will be delivered over at&#xD;
             least 5 weeks and that will expose the brain to radiation&#xD;
&#xD;
          -  Patients must have Karnofsky performance status (KPS) &gt;= 80&#xD;
&#xD;
          -  Patients must be able to obtain an MRI scan with gadolinium contrast&#xD;
&#xD;
          -  Female patients of childbearing age must not be pregnant as determined with a serum&#xD;
             beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study&#xD;
             registration, or breast-feeding. (The exclusion is made because gadolinium may be&#xD;
             teratogenic in pregnancy). Pregnancy tests are part of standard of care routine if a&#xD;
             patient is receiving radiation treatment&#xD;
&#xD;
          -  Patient must be fluent enough in English to complete neurocognitive testing&#xD;
&#xD;
          -  Education of &gt;= 12 years (high school graduate or equivalent) by patient self-report&#xD;
&#xD;
          -  Patient is able to complete an in-person and electronic neurocognitive assessments&#xD;
             (i.e. is alert and has the ability to comprehend and complete the assessments)&#xD;
&#xD;
          -  Patient has no history of psychiatric or medical conditions that would result in an&#xD;
             inability to complete serial neurocognitive tests, severe claustrophobia, prior&#xD;
             cerebrovascular event(s), degenerative neurological diagnoses (e.g., dementia,&#xD;
             Parkinson's, multiple sclerosis [MS]) or severe psychiatric illness (e.g.,&#xD;
             schizophrenia) that may impact neurocognitive and imaging assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiation to the brain&#xD;
&#xD;
          -  Concurrent chemotherapy&#xD;
&#xD;
          -  Psychiatric or medical conditions that would result in inability to complete serial&#xD;
             neurocognitive tests&#xD;
&#xD;
          -  Severe claustrophobia requiring sedative medications for the MRI&#xD;
&#xD;
          -  Prior cerebrovascular event(s) or degenerative neurological diagnoses (e.g., dementia,&#xD;
             Parkinson's, MS)&#xD;
&#xD;
          -  Contraindication to gadolinium-based contrast administration for MRI (i.e. allergy to&#xD;
             gadolinium or severe chronic kidney disease defined by estimated glomerular filtration&#xD;
             rate [eGFR] &lt; 30 mL/min/1.73 m^2, as per institutional policy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Chung</last_name>
    <phone>713-563-2300</phone>
    <email>cchung3@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Chung</last_name>
      <phone>713-563-2300</phone>
      <email>cchung3@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Caroline Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M.D. Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

